Zhang GY, et al. - Researchers evaluated the role of neoadjuvant bleomycin, etoposide, and cisplatin (BEP) regimen in patients with extensively advanced yolk sac tumors (YSTs). Researchers identified a total of 58 patients with YST who underwent initial treatment at their institution between July 1982 and December 2015, of whom 18 were deemed inoperable and received neoadjuvant BEP regimen. Outcomes revealed that in extensively advanced patients with YSTs, one or 2 cycles of neoadjuvant BEP regimen followed by cytoreductive surgery offer a chance for cure and help pave the way for fertility-sparing surgery.